Ignite Creation Date:
2024-05-19 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06416241
Status:
COMPLETED
Last Update Posted:
2024-05-16
First Post:
2024-05-08
Brief Title:
Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion
Sponsor:
University of Athens
Organization:
University of Athens
Study Overview
Official Title:
Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
INTRAMED-CRVO
Brief Summary:
Central retinal vein occlusion CRVO is a common retinal vascular disorder occurring when there is a blockage to the main blood vessel that transports blood away from the retina CRVO may cause visual impairment especially due to macular edema swelling of the macula due to fluid accumulation and macular non-perfusion
Aflibercept has been found to improve visual acuity and reduce macular thickness in pivotal trials
The purpose of this study was to evaluate the efficacy and safety of intravitreal aflibercept in real-world using a patient-fitted treatment regimen Additionally imaging parameters have been assessed before and after treatment with intravitreal aflibercept
Aflibercept has been found to improve visual acuity and reduce macular thickness in pivotal trials
The purpose of this study was to evaluate the efficacy and safety of intravitreal aflibercept in real-world using a patient-fitted treatment regimen Additionally imaging parameters have been assessed before and after treatment with intravitreal aflibercept
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
True
Is an FDA AA801 Violation?:
None